75000 - Document - Document and Entity Information
link:presentationLink
link:calculationLink
link:definitionLink
75010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
link:presentationLink
link:calculationLink
link:definitionLink
75020 - Disclosure - Loss per Share - Schedule of Computation of Diluted Net Loss per Common Share (Details) 2
link:presentationLink
link:calculationLink
link:definitionLink
75030 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
link:presentationLink
link:calculationLink
link:definitionLink
75050 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY/(DEFICIT) (UNAUDITED)
link:presentationLink
link:calculationLink
link:definitionLink
75060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY/(DEFICIT) (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75070 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
link:presentationLink
link:calculationLink
link:definitionLink
995455 - Disclosure - Basis of Presentation and New Accounting Standards
link:presentationLink
link:calculationLink
link:definitionLink
995465 - Disclosure - Use of Estimates
link:presentationLink
link:calculationLink
link:definitionLink
995475 - Disclosure - Liquidity and Going Concern
link:presentationLink
link:calculationLink
link:definitionLink
995485 - Disclosure - Fair Value Measurements
link:presentationLink
link:calculationLink
link:definitionLink
995495 - Disclosure - Loss per Share
link:presentationLink
link:calculationLink
link:definitionLink
995505 - Disclosure - Grant Revenue
link:presentationLink
link:calculationLink
link:definitionLink
995515 - Disclosure - Commitments and Contingencies
link:presentationLink
link:calculationLink
link:definitionLink
995525 - Disclosure - Composition of Certain Financial Statement Captions
link:presentationLink
link:calculationLink
link:definitionLink
995535 - Disclosure - Line of Credit Facility
link:presentationLink
link:calculationLink
link:definitionLink
995545 - Disclosure - License Agreements
link:presentationLink
link:calculationLink
link:definitionLink
995555 - Disclosure - Biocept Asset Acquisitions
link:presentationLink
link:calculationLink
link:definitionLink
995565 - Disclosure - Stockholders' Equity
link:presentationLink
link:calculationLink
link:definitionLink
995575 - Disclosure - Stock-based Compensation
link:presentationLink
link:calculationLink
link:definitionLink
995585 - Disclosure - Segment Information
link:presentationLink
link:calculationLink
link:definitionLink
995595 - Disclosure - Subsequent Events
link:presentationLink
link:calculationLink
link:definitionLink
995605 - Disclosure - Basis of Presentation and New Accounting Standards (Policies)
link:presentationLink
link:calculationLink
link:definitionLink
995615 - Disclosure - Fair Value Measurements (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995625 - Disclosure - Loss per Share (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995635 - Disclosure - Composition of Certain Financial Statement Captions (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995645 - Disclosure - Stockholders' Equity (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995655 - Disclosure - Stock-based Compensation (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995665 - Disclosure - Segment Information (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995675 - Disclosure - Basis of Presentation and New Accounting Standards - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995685 - Disclosure - Liquidity and Going Concern - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995695 - Disclosure - Fair Value Measurements - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995705 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995715 - Disclosure - Fair Value Measurements - Summary of Key Level 3 Inputs Used in Fair Value (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995725 - Disclosure - Fair Value Measurements - Schedule of Change in Fair Value of Liability (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995735 - Disclosure - Fair Value Measurements - Summary of Key Level 3 Inputs Used in Valuation of Warrants Liability at Fair Value (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995745 - Disclosure - Loss per Share - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995755 - Disclosure - Loss per Share - Schedule of Antidilutive Securities Excluded from Diluted Loss per Share (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995765 - Disclosure - Loss per Share - Schedule of Computation of Basic Net Loss per Common Share (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995775 - Disclosure - Loss per Share - Schedule of Computation of Diluted Net Loss per Common Share (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995785 - Disclosure - Grant Revenue - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995795 - Disclosure - Commitments and Contingencies - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995805 - Disclosure - Composition of Certain Financial Statement Captions - Other Current Assets (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995815 - Disclosure - Line of Credit Facility - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995825 - Disclosure - License Agreements - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995835 - Disclosure - Biocept Asset Acquisitions - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995845 - Disclosure - Stockholders' Equity - Preferred Stock (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995855 - Disclosure - Stockholders' Equity - Common stock (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995865 - Disclosure - Stockholders' Equity - Summary of Warrants Outstanding (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995875 - Disclosure - Stock-based Compensation - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995885 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995895 - Disclosure - Segment Information - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995905 - Disclosure - Segment Information - Schedule of Segment Expenses (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995915 - Disclosure - Subsequent Events - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
Period for regain compliance.
Period For Regain Compliance
Period for regain compliance
Costs of acquisitions
Business Combination, Acquisition-Related Cost, Expense
Proceeds from sale of property and equipment
Proceeds from Sale of Property, Plant, and Equipment
Proceeds from Sale of Property, Plant, and Equipment, Total
May 2024 Private Placement
May 2024 Private Placement [Member]
May 2024 private placement.
Proceeds from Issuance of Notes Payable and Warrants
Proceeds from issuance of notes payable and warrants.
Issuance of notes payable and warrants
Entity Incorporation State Country Code
Entity Incorporation, State or Country Code
Facility And Other Overhead Expenses [Member]
Facility And Other Overhead Expenses [Member]
Preferred Stock Shares Issued
Preferred stock, shares issued (in shares)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
Fair value
Beginning balance as of January 1, 2025
Ending balance as of June 30, 2025
Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]
Supplemental schedule of non-cash investing and financing activities:
New Capital Subscriptions [Member]
New Capital Subscriptions.
Plan Name
Plan Name [Axis]
Entity Current Reporting Status
Entity Current Reporting Status
Proceeds from Warrant Exercises
Proceeds from exercise of Series B Warrants from May 2024 PIPE
Operating Expenses [Abstract]
Operating expenses:
Fair Value, Inputs, Level 2 [Member]
Level 2 [Member]
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward
Weighted Average Exercise Price [Roll Forward]
Commitments And Contingencies Disclosure [Text Block]
Commitments and Contingencies
Common Stock Shares Authorized
Common stock, shares authorized (in shares)
Net of offering costs
Net Of Offering Costs
Net of offering costs.
Product and Service [Axis]
Preferred stock, voting rights
Preferred Stock, Voting Rights
Fair Value by Liability Class [Domain]
Document Fiscal Period Focus
Document Fiscal Period Focus
Interest rate
Debt Instrument, Interest Rate, Stated Percentage
Maximum interest rate
Revenue from Contract with Customer [Abstract]
Entity Shell Company
Entity Shell Company
Contractual Obligation
Contractual obligation
Contractual Obligation, Total
Warrant issuance expenses
Warrant issuance expenses
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances
Issuance
Cash And Cash Equivalents At Carrying Value
Cash and cash equivalents
Cash and Cash Equivalents, at Carrying Value, Total
Warrant Liabilities
Warrant liabilities.
Warrant liability
Series B Warrants [Member]
Series B warrants.
Research And Development Arrangement Contract To Perform For Others By Type [Axis]
Research and Development Arrangement, Contract to Perform for Others, Type
Common Stock Shares Issued
Common stock, shares issued (in shares)
Statement [Table]
Statement [Table]
Closing Stock Price Not Below Zero Point Five Zero [Member]
Closing Stock Price Not Below Zero Point Five Zero.
Closing Stock Price Not Below $0.50 [Member]
Statement [Line Items]
Statement [Line Items]
Purchase of treasury stock
Treasury Stock, Value, Acquired, Cost Method
Purchase of treasury stock
Grant Revenue Recognition
Revenue from Contract with Customer [Policy Text Block]
Warrant [Member]
Outstanding Warrants [Member]
Entity Filer Category
Entity Filer Category
Liabilities And Stockholders Equity
Total liabilities and stockholders' equity
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
Exercisable at June 30, 2025 (in dollars per share)
Cash equivalents
Cash and Cash Equivalents, Fair Value Disclosure
Cash paid during period for:
Cash Paid During Period For [Abstract]
Cash paid during period for:
Congressionally Directed Medical Research Programs [Member]
Congressionally directed medical research programs.
Warrant liability
Warrant Liability Noncurrent
Warrant liability noncurrent.
Carrying value of warrants exchanged
Change In Fair Value Of Warrants
Change in fair value of warrants.
Change in fair value of warrant liabilities
Subsequent Event [Line Items]
Two thousand eighteen rights offering.
Two Thousand Eighteen Rights Offering [Member]
2018 Rights Offering [Member]
Goodwill
Goodwill
Goodwill, Total
Goodwill, Beginning Balance
Goodwill, Ending Balance
Investment Income Interest
Interest income
Treasury Stock, Common, Value
Treasury stock (at cost, 258,425 shares as of March 31, 2025 and December 31, 2024, respectively
Treasury stock (at cost), 258,425 shares as of June 30, 2025 and December 31, 2024, respectively
Purchase of intangible assets
Payments to Acquire Intangible Assets
Preferred stock dividend rate percentage eliminated date.
Preferred Stock Dividend Rate Percentage Eliminated Date
Series A 3.6% Convertible preferred stock eliminated date
Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited
Cancellation of common stock (in Shares)
Cancellation of common stock (in Shares)
Initial Subscription [Member]
Initial Subscription.
Rights related to distribution of assets
Rights Related To Distribution Of Assets
Rights related to distribution of assets.
SPEA Warrants [Member]
SPEA Warrants.
Percentage of grant proceeds with interest not exceed annually.
Percentage Of Grant Proceeds With Interest Not Exceed Annually
Percentage of grant proceeds with interest not exceed annually
Stock Issued During Period, Value, Reclassification of warrants to equity
Stock issued during period, value, reclassification of warrants to equity.
Reclassification of 2025 Series B warrant liability to equity
Series A Warrants [Member]
Series A Warrants [Member]
Exchange Of Warrants For Notes Payable
Exchange of warrants for notes payable.
Exchange of warrants for notes payable
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
Common stock shares to be issued (in shares)
Granted (in shares)
Disaggregation of Revenue [Table]
March Two Thousand Twenty Five Series B Warrants [Member]
March Two Thousand Twenty Five Series B Warrants [Member]
March 2025 Series B Warrants [Member]
Earnings Per Share Basic
Net loss per share, basic
Net income (loss) per share of common stock - basic
Debt Securities, Available-for-Sale, Premium on Purchased Options [Policy Text Block]
Available-for-Sale Securities
Principal payments of term loan obligation
Repayments Of Long Term Debt
Repayments of Long-Term Debt, Total
Payments for Repurchase of Equity, Total
Payments for Repurchase of Equity
Purchase of treasury stock
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
Balance as of December 31, 2024 (in shares)
Balance as of June 30, 2025 (in shares)
Loss on disposal of property and equipment
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property
Gain on sale of assets
Liabilities Current
Total current liabilities
Maximum Obligation Under Single Regular Purchase
Maximum obligation under single regular purchase.
Maximum obligation under single regular purchase
Warrants Policy [Policy Text Block]
Warrants Policy.
Warrants
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]
Adjustments to reconcile net loss to net cash used in operating activities:
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
Schedule of Change in Fair Value of Liability
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reclassified To Equity
Fair value measurement with unobservable inputs reconciliation recurring basis liability reclassified to equity.
Reclassified to equity
Exercise of pre-funded warrants (in Shares)
Exercise Of Pre-funded Warrants Shares
Exercise of pre-funded warrants shares.
License agreement abstract.
License Agreement [Abstract]
Percentage of liquidated damages obligated to pay
Percentage of liquidated damages obligated to pay
Stockholders Equity [Abstract]
Stockholders' equity (deficit):
Support Letter Participation Rights Period
Support letter participation rights period.
Support letter participation rights period
Entity Small Business
Entity Small Business
Series A convertible preferred stock.
Series A Convertible Preferred Stock [Member]
Series A Convertible Preferred Stock [Member]
Accumulated deficit
Retained Earnings Accumulated Deficit
Accumulated deficit
Retained Earnings (Accumulated Deficit), Total
Issuance Of Common Stock, Prefunded Warrants And Warrants For Debt Repayment
Issuance of common stock, prefunded warrants and warrants for debt repayment.
Issuance of common stock, pre-funded warrants and warrants for debt repayment
Preferred Stock [Member]
Preferred Stock [Member]
Convertible Preferred Stock [Member]
Grants Receivable, Current
Grant receivable
Closing Stock Price Not Below $0.75 [Member]
Closing Stock Price Not Below Zero Point Seven Five [Member]
Closing Stock Price Not Below Zero Point Seven Five.
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
Cancelled/forfeited (in shares)
Warrants and Rights Outstanding, Measurement Input
Warrant liability, Measurement input
Disclosure Of Compensation Related Costs Share Based Payments [Text Block]
Stock-based Compensation
Purchase of short-term investments
Payments to Acquire Short-Term Investments
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]
Potential financing percentage
Potential Financing Percentage
Potential financing percentage.
Amendment Flag
Amendment Flag
Product and Service [Domain]
Regain Compliance Expiry Date
Regain compliance expiry date.
Regain compliance expiry date
Percentage Agreed to Repay Purchasers Holding Securities
Percentage agreed to repay purchasers holding securities.
Percentage agreed to repay purchasers holding securities
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
Number of shares callable by warrants (in shares)
Number of securities called by warrant or right
Liabilities And Stockholders Equity [Abstract]
Liabilities and Stockholders' Equity (Deficit)
Entity Address Postal Zip Code
Entity Address, Postal Zip Code
Net Cash Provided By Used In Operating Activities
Net cash used in operating activities
Net cash used in operating activities
Change in operating lease liabilities
Increase (Decrease) in Operating Lease Liability
Common Stock [Member]
Common Stock [Member]
Accounting Standards Update and Change in Accounting Principle [Table]
Maximum Value of Shares to be Issued Under Agreement
Maximum value of shares to be issued under agreement.
Maximum value of shares to be issued under agreement
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
Granted (in dollars per share)
Research And Development Arrangement Contract To Perform For Others Type [Domain]
Research and Development Arrangement, Contract to Perform for Others, Type
Entity Address Address Line1
Entity Address, Address Line One
Change in accounting principle, accounting standards update, immaterial effect
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]
Fair Value Hierarchy and NAV [Axis]
Earnings Per Share [Abstract]
Supplemental Cash Flow Information [Abstract]
Supplemental disclosure of cash flows information:
Percentage of Proceeds to Repay Purchasers from Capital Raised
Percentage of proceeds to repay purchasers from capital raised.
Percentage of proceeds to repay purchasers from capital raised
February Two Thousand Twenty Five Securities Purchase and Exchange Agreements [Member]
February two thousand twenty five securities purchase and exchange agreements.
February 2025 SPEA Agreements
Stock based compensation 2015 equity incentive plan 1 member.
Stock Based Compensation2015 Equity Incentive Plan1 [Member]
2015 Plan [Member]
Investment Type [Axis]
Investment Type
March 2025 Series A and B Warrants [Member]
March Two Thousand Twenty Five Series A and B Warrants [Member]
March two thousand twenty five series A and B warrants.
Operating Lease Right Of Use Asset
Operating lease right-use-of assets
Redemption of short-term investments
Redemption of Short-Term Investments
Redemption of Short-Term Investments
Pershing Credit Facility [Member]
Pershing Credit Facility [Member]
Pershing Credit Facility.
Charlottesville
Charlottesville [Member]
Charlottesville [Member]
Class Of Warrant Or Right [Axis]
Class of Warrant or Right
Expiration period
Class of Warrant or Right Expiration Period
Class of warrant or right expiration period.
Document Type
Document Type
Exchange Notes [Member]
Exchange notes.
Exchange Notes
Type Of Arrangement [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative
Arrangements And Nonarrangement Transactions [Member]
Collaborative Arrangement and Arrangement Other than Collaborative
Entity Central Index Key
Entity Central Index Key
Line of Credit Facility [Table]
Asset Acquisition [Table]
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
Net increase (decrease) in cash and cash equivalents
Subsequent Event Type [Domain]
Fair value of warrant liability
Change in fair value of warrants
Fair Value Adjustment Of Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
Dilutive common shares excluded from the calculations of diluted loss per share (in shares)
Short-Term Debt [Text Block]
Line of Credit Facility
Disclosure of accounting policy for license agreement.
License Agreement Disclosure [Text Block]
License Agreements
Common Stock Par Or Stated Value Per Share
Common stock, par value (in dollars per share)
Proceeds from Issuance of Warrants
Proceeds from issuance of warrants
Prefunded Warrant [Member]
Prefunded Warrant.
Reduction in the carrying amount of operating lease right-of-use assets
Operating Lease, Right-of-Use Asset, Periodic Reduction
Options.
Options [Member]
Outstanding Stock Options [Member]
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
Balance as of June 30, 2025
Debt Securities, Available-for-Sale, Amortized Cost
Debt Securities, available-for-sale, amortized cost and fair value
Amortized Cost
Amortized Cost
Aggregate Purchase Price
Aggregate purchase price.
Aggregate purchase price
Potential Cash Payment
Potential cash payment.
Potential cash payment
Other Prepaid Expense, Current
Prepaid services
Professional Expenses [Member]
Professional expenses.
Fair Value Measurement Inputs Disclosure [Text Block]
Fair Value Measurements
Marketable Securities
Marketable Securities, Total
Collateralized marketable securities
Financing expense
Financing Expense
Financing expense.
Grant payment received
Proceeds from Grants Received
Proceeds from grants received.
Series F Preferred Stock [Member]
Series F Preferred Stock [Member]
Current Fiscal Year End Date
Current Fiscal Year End Date
Modification Period
Modification period.
Modification period
Document Quarterly Report
Document Quarterly Report
Distribution Type [Domain]
Lincoln park capital fund, LLC.
Lincoln Park Capital Fund L L C [Member]
Lincoln Park Capital Fund, LLC [Member]
Entity Address State Or Province
Entity Address, State or Province
Additional Accelerated Purchase Price Per share Threshold Percentage
Additional accelerated purchase price per share threshold percentage.
Additional accelerated purchase price per share threshold percentage
Stock Issued During Period Value Conversion Of Convertible Securities
Conversion of Series B Convertible Preferred Stock into common stock
Consideration paid to preferred stock holders
Consideration Paid To Preferred Stock Holders
Consideration paid to preferred stock holders.
Use of Estimates [Abstract]
Use Of Estimates [Abstract]
Asset Acquisition [Domain]
Preferred Stock Shares Outstanding
Preferred stock, shares outstanding (in shares)
Preferred Stock, Shares Outstanding, Beginning Balance
Preferred Stock, Shares Outstanding, Ending Balance
Class Of Warrant Or Right [Domain]
Class of Warrant or Right
Increase Decrease In Grant Receivable
Increase decrease in grant receivable.
Grant receivable
Payments For Royalties
License fee payment in cash
Refers to the period exercisable from the date of issuance.
Period Exercisable From The Date Of Issuance
Period exercisable from the date of issuance
Issuance Of Common Stock Shares, Prefunded Warrants And Warrants For Debt Repayment
Issuance of common stock shares, prefunded warrants and warrants for debt repayment.
Issuance of common stock, pre-funded warrants and warrants for debt repayment (in shares)
Consecutive business days.
Consecutive Business Days
Consecutive business days
Subsequent Event [Member]
Subsequent Event [Member]
May 2024 Series B Warrants [Member]
May Two Thousand Twenty Four Series B Warrants [Member]
May Two Thousand Twenty Four Series B Warrants Member.
Contract effective date.
Contract Effective Date
Contract effective date
Other Assets Noncurrent
Other assets
Fair Value Measurement Inputs and Valuation Techniques [Table]
Revenue, Product and Service [Extensible Enumeration]
Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
Stock option vesting percentage
Basis Of Presentation And Significant Accounting Policies [Text Block]
Basis of Presentation and New Accounting Standards
May 2024 Purchase Agreement
May Two Thousand Twenty Four Purchase Agreement [Member]
May two thousand twenty four purchase agreement.
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Vested and expected to vest as of June 30, 2025
Exercisable at June 30, 2025
Closing Stock Price Not Below Zero Point One Zero [Member]
Closing Stock Price Not Below Zero Point One Zero.
Closing Stock Price Not Below $0.10 [Member]
Stock issued during period shares warrants exercise(shares).
Stock Issued During Period Shares Warrants Exercise Shares
Exercise of Series B Warrants from May 2024 PIPE (in shares)
Treasury stock, shares
Treasury Stock, Common, Shares
Balance, Treasury (in shares)
Balance, Treasury (in shares)
Cash and Cash Equivalents [Domain]
Diluted net loss per common share calculation:
Earnings Per Share, Diluted, Two Class Method [Abstract]
Maximum beneficial ownership percentage
Maximum Beneficial Ownership Percentage
Maximum beneficial ownership percentage.
Lessee Operating Lease Option To Extend
Lessee, operating lease, option to extend
Preferred Stock Value
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,952 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively
Debt Instrument Maturity Date
Maturity date
Minimum [Member]
Minimum [Member]
Financial Instrument [Axis]
Financial Instrument
Assets Current [Abstract]
Current assets:
Recorded Unconditional Purchase Obligation [Table]
Recorded Unconditional Purchase Obligation [Table]
Liquidity Abstract
Liquidity [Abstract]
Level 3 [Member]
Fair Value, Inputs, Level 3 [Member]
Cancelled/forfeited
Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled or Forfeited In Period Total Intrinsic Value
Share based compensation arrangement by share based payment award options cancelled or forfeited in period total intrinsic value.
Initial commitment shares.
Initial Commitment Shares
Initial commitment shares
Modification and extinguishment
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Modification and Extinguishment
Fair value measurement with unobservable inputs reconciliation recurring basis liability modification and extinguishment.
Segment Reporting [Abstract]
Summary of Financial Assets Measured at Fair Value on Recurring Basis
Fair Value, Assets Measured on Recurring Basis [Table Text Block]
Liabilities Current [Abstract]
Current liabilities:
Shares Outstanding
Balance (in shares)
Balance (in shares)
Commitments And Contingencies
Commitments and contingencies (Note 7)
Offering Costs
Offering costs.
Offering expenses
March 2025 Private Placement [Member]
March Two Thousand Twenty Five Private Placement [Member]
March Two Thousand Twenty Five Private Placement.
March 2025 Private Placement
Deferred grant liability
Deferred Income, Current
Debt Instrument Basis Spread On Variable Rate1
Basis variable rate
Basis variable rate
Stockholders' Equity, Reverse Stock Split
Reverse stock split
Preferred Stock Dividend Rate Percentage
Convertible preferred stock
Forecast [Member]
Forecast [Member]
Additional Commitment Fee
Additional commitment fee.
Additional commitment fee paid in cash
Contract termination date.
Contract Termination Date
Contract termination date
Remeasurement of Warrant Liability
Remeasurement of warrant liability.
Remeasurement of warrant liability
Line of Credit Facility [Abstract]
Weighted Average Number Of Shares Outstanding Basic
Weighted average common shares outstanding - basic
Weighted average number of shares of common stock outstanding - basic
Scenario [Axis]
Earnings Per Share, Basic, Two Class Method [Abstract]
Basic net loss per common share calculation:
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value
Exercisable at June 30, 2025
Segment Reporting, Expense Information Used by CODM, Description
Segment Reporting, Expense Information Used by CODM, Description
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent, Total
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent
Net income from continuing operations
Grant funding term.
Grant Funding Term
Grant funding term
Proceeds from private placement
Proceeds from Issuance of Private Placement
Subsequent Events [Text Block]
Subsequent Events
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
Stock-based compensation
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total
Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted
Income attributable to 2025 Warrants
Stockholders' deficit
Stockholders Equity
Balance
Balance
Total stockholders' equity (deficit)
Stockholders' equity
Preferred Stock Par Or Stated Value Per Share
Preferred stock, par value (in dollars per share)
Basis Of Accounting Policy Policy [Text Block]
Basis of Presentation and New Accounting Standards
Statement Of Stockholders Equity [Abstract]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Use of Estimates
Use of Estimates, Policy [Policy Text Block]
Treasury Stock, Common [Member]
Treasury Stock [Member]
Entity Address Address Line2
Entity Address, Address Line Two
Letter Agreement [Member]
Letter Agreement.
Letter Agreement [Member]
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward
Options [Roll Forward]
Other Assets Current
Other current assets
Total other current assets
Maximum Beneficial Ownership Percentage By Election Of Holder
Maximum beneficial ownership percentage by election of holder.
Maximum beneficial ownership percentage by election of holder
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]
Plan Name [Domain]
Plan Name
Initial commitment fee.
Initial Commitment Fee
Initial commitment fee paid in cash
Initial commitment fee
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
Settlement
Excess of fair value of instruments issued over cash received
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Entity [Domain]
Credit Facility [Axis]
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
Vested and expected to vest at June 30, 2025 (in dollars per share)
Series F Convertible Preferred Stock [Member]
Series F Convertible Preferred Stock.
Class Of Warrant Or Right Outstanding
Class of warrant outstanding
Number of base warrant shares at issuance
Treasury Stock, Value, Total
Treasury Stock, Value
Treasury stock
Exercise of March 2025 Series B Warrants (in Shares)
Stock Issued During Period, Shares, Exercise of Series B Warrants
Stock issued during period, shares, exercise of Series B warrants.
Related Party Transactions By Related Party [Axis]
Related Party
Asset Acquisition [Text Block]
Biocept Asset Acquisitions
Class of Warrant or Right [Table]
Accounting Standards Update [Extensible Enumeration]
Entity Address City Or Town
Entity Address, City or Town
Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]
Schedule of Computation of Diluted Net Loss per Share of Common Share
Stock Repurchased During Period, Shares
Number of stock repurchased
Accelerated purchase price per share threshold percentage
Accelerated Purchase Price Per share Threshold Percentage
Accelerated purchase price per share threshold percentage.
Security Exchange Name
Security Exchange Name
Credit Facility [Domain]
Clinical Development and Licensing Expenses [Member]
Clinical Development and Licensing Expenses.
Share based compensation arrangement by share based payment award options aggregate intrinsic value.
Aggregated Intrinsic Value [Roll Forward]
Share Based Compensation Arrangement by Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
Vested and expected to vest at June 30, 2025 (in shares)
Measurement Input Type [Domain]
Nano Tx license agreement Member
Nano Tx Licenses Agreement [Member]
Nano Tx Licenses Agreement [Member]
Convertible Notes Term
Convertible notes term.
Stockholders Equity Note [Abstract]
Disclosure of liquidity and going concern text block
Liquidity and Going Concern
Disclosure Of Liquidity And Going Concern Text Block
Interest Paid Net
Interest
Statistical Measurement [Domain]
Range [Member]
Statistical Measurement
Warrant exercise price (in dollars per share)
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
Assets Current
Total current assets
Extinguishment of Warrants
Extinguishment of Warrants
Extinguishment of Warrants
Document Period End Date
Document Period End Date
Other Income And Expenses [Abstract]
Other income (expense):
Fair Value Hierarchy and NAV [Domain]
Adjustments To Additional Paid In Capital Modification Of Warrants
Adjustments to additional paid in capital, modification of warrants.
Modification of warrants (Note 12)
Research And Development Award In Period
Research and development award in period.
Research and development award in period
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
Exercisable at June 30, 2025 (in shares)
Line of Credit Facility, Commitment Fee Percentage
Applicable fees
Percentage of non-dilutive monetary awards required to pay
Percentage of Non-dilutive Monetary awards Required to Pay
Percentage of non-dilutive monetary awards required to pay.
Series C convertible preferred stock.
Series C Convertible Preferred Stock [Member]
Series C Convertible Preferred Stock [Member]
First Payment Received
First Payment Received
First payment received
Statement Of Financial Position [Abstract]
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer.
Pre Clinical Research Study Obligations [Member]
Pre-clinical Research Study Obligations [Member]
Statement Class Of Stock [Axis]
Class of Stock
Class Of Warrant Or Right Warrants Exercise Ratio
Class Of Warrant Or Right Warrants Exercise Ratio.
Warrants exercise ratio
Liabilities
Total liabilities
Operating lease discount rate
Lessee, Operating Lease, Discount Rate
Minimum Stockholders Equity Requirement Date
Minimum stockholder's equity requirement date.
Minimum stockholder's equity requirement date
Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]
Financial Instruments
Additional Subscription [Member]
Additional Subscription.
Series B convertible preferred stock.
Series B Convertible Preferred Stock [Member]
Series B Convertible Preferred Stock [Member]
Prepaid Expense and Other Assets, Current [Abstract]
Weighted Average Number Of Diluted Shares Outstanding
Weighted average common shares outstanding - diluted
Weighted average number of shares of common stock outstanding - diluted
Entity File Number
Entity File Number
Cover [Abstract]
Change in fair value of derivative instruments
Change In Fair Value Of Derivative Instruments
Change in fair value of derivative instruments.
Change in fair value of derivative instruments
Percentage of aggregate amount of proceeds awarded under CPRIT grant.
Percentage Of Aggregate Amount Of Proceeds Awarded Under CPRIT Grant
Percentage of aggregate amount of proceeds awarded under CPRIT grant
Number Of Votes Per Share
Number of votes per share.
Exchange of Warrant for Notes Payable
Exchange of warrant for notes payable.
Exchange of warrants for notes payable
Measurement Input Type [Axis]
Increase Decrease In Accounts Payable And Accrued Liabilities
Accounts payable and accrued expenses
Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total
Closing bid price for common stock had fallen.
Closing Bid Price For Common Stock Had Fallen Below
Closing bid price for common stock had fallen below
Investment Type Categorization [Member]
Investments
Supplemental Balance Sheet Disclosures [Text Block]
Composition of Certain Financial Statement Captions
Scenario [Domain]
US Treasury Securities [Member]
U.S. Treasury Securities [Member]
Treasury Bills and Treasury Note[Member]
Distribution Type [Axis]
Number of operating segment
Number of Operating Segments
Sale Of Stock Name Of Transaction [Domain]
Sale of Stock
Segment Information
Segment Reporting Disclosure [Text Block]
Maintain minimum market value of listed securities
Maintain minimum market value of listed securities
Maintain Minimum Market Value of Listed Securities
General And Administrative Expense
General and administrative
Total general and administrative
Subsequent Event [Table]
CPRIT grant funding term.
CPRIT Grant Funding Term
CPRIT grant funding term, description
Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table]
Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract]
Weighted Average Remaining Contractual Life (years) [Roll Forward]
Financing percentage after modification period
Financing Percentage After Modification Period
Financing percentage after modification period.
New Accounting Pronouncements, Policy [Policy Text Block]
Recently Issued Accounting Pronouncements
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Stock Issued During Period Shares Conversion Of Convertible Securities
Conversion of Series B Convertible Preferred Stock into common stock (share)
Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
Stock option vesting period
Common Stock Shares Outstanding
Common stock, shares outstanding (in shares)
Common Stock, Shares, Outstanding, Beginning Balance
Common Stock, Shares, Outstanding, Ending Balance
Operating Lease Liability Current
Operating lease liability
Less: current portion
Convertible Notes [Member]
Convertible notes.
Depreciation Depletion And Amortization
Depreciation and amortization
Depreciation, Depletion and Amortization, Total
Document Transition Report
Document Transition Report
Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]
Short-Term Investments, Total
Short-Term Investments
Investments
Operating Expenses
Total operating expenses
Research and development expense
Research And Development Expense
Research and development
Total research and development
Convertible Preferred Stock [Member]
Convertible Preferred Stock [Member]
Statement Of Cash Flows [Abstract]
Number of warrants exercised
Number Of Warrants Exercised
Number of warrants exercised
Stockholders' equity requirement
Issue and sale of stock, net
Issuance of common stock
Deferred grant liability
Increase (decrease) in deferred grant liability.
Increase Decrease In Deferred Grant Liability
Fair value of warrant liability reclassified to equity
Fair Value of Warrant Liability Reclassified to Equity
Fair Value of Warrant Liability Reclassified to Equity
Number Of Shares Issuable Upon Exercise
Number of shares issuable upon exercise.
Number of shares issuable upon exercise
Amount To Be Received As Award For Research And Development
Amount to be received as award for research and development.
Amount to be received as award for research and development
Composition of Certain Financial Statement Captions [Abstract]
Composition Of Certain Financial Statement Captions [Abstract]
Funding Notes [Member]
Funding notes.
Funding Notes
Stockholders Equity Note Disclosure [Text Block]
Stockholders' Equity
Earnings Per Share [Text Block]
Loss per Share
Net income (loss)
Net income (loss)
Warrant Issuance Costs
Warrant issuance costs.
Warrant issuance costs
Warrant issuance costs
Warrant issuance expenses
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Balance as of December 31, 2024
Balance as of June 30, 2025
Private Placement And Prefunded Warrant [Member]
Private Placement and Prefunded Warrant[Member]
Private Placement and Prefunded Warrant.
Other Intangible Assets Net
Intangible assets, net
Warrant liability, Remaining term (years)
Warrants And Rights Outstanding Term
Warrants expected term
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Exercise of pre-funded warrants
Exercise Of Pre-funded Warrants
Exercise of pre-funded warrants.
Exercise of pre-funded warrants
Potential liquidated damages payment liability
Potential liquidated damages payment liability
Line of Credit Facility [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
Vested and expected to vest as of March 31, 2025
Assets
Assets [Abstract]
Amortization Of Financing Costs And Discounts
Amortization of deferred financing costs and debt discount
Amortization of Debt Issuance Costs and Discounts, Total
Grant Advance Payment
Grant advance payment.
Grant advance payment
Document Fiscal Year Focus
Document Fiscal Year Focus
Debt Instrument, Measurement Input
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total
Change in fair value
Changes in the fair value of Notes
Issuance Of Common Stock, Prefunded Warrants And Warrants, Net Of Offering Costs
Issuance of common stock, prefunded warrants and warrants, net of offering costs .
Issuance of common stock, prefunded warrants and warrants, net of offering costs
Net Cash Provided By Used In Investing Activities [Abstract]
Cash flows used in investing activities:
Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]
Schedule of Computation of Basic Net Loss per Common Share
Number of maximum common shares can be resale
Number of Maximum Common Shares Can Be Resale
Number of maximum common shares can be resale.
Interest expense
Interest Expense, Nonoperating
Interest Expense, Nonoperating, Total
Accounting Standards Update and Change in Accounting Principle [Abstract]
Deferred Revenue
Deferred Revenue, Total
Deferred grant liability
Fair Value Disclosures [Abstract]
Commitments And Contingencies Disclosure [Abstract]
Undistributed Earnings (Loss) Available to Common Shareholders, Diluted
Net income (loss) attributable to common stockholders
Consideration to purchaser in cash
Sale of Stock, Consideration Received on Transaction
Net Income (Loss) Available to Common Stockholders, Basic
Net income (loss) attributable to common stockholders - basic
Stock issued during period shares warrants exercise.
Stock Issued During Period Shares Warrants Exercise
Exercise of Series B Warrants from May 2024 PIPE
Line of credit
Long-Term Line of Credit
Long-Term Line of Credit, Total
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
Total unamortized compensation cost related to outstanding unvested stock options and restricted stock awards
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total
Assets, Fair Value Disclosure, Total
Assets, Fair Value Disclosure
Fair Value
Subsidiary Sale Of Stock [Axis]
Sale of Stock
Revenues, Total
Revenues
Revenue
Revenue recognized
Net Cash Provided By Used In Investing Activities
Net cash used in investing activities
Private Placement Share [Member]
Private Placement [Member]
Undistributed Earnings (Loss) Allocated to Participating Securities, Basic
Income attributable to 2025 Warrants
Security12b Title
Title of 12(b) Security
Schedule of Segment Reporting Information, by Segment [Table]
purchase price of share
purchase price of share.
Purchase price of share
Remained authorized amount for repurchase
Share Repurchase Program, Remaining Authorized, Amount
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
Cancelled/forfeited (in dollars per share)
Money Market Funds [Member]
Money Market [Member]
Related and Nonrelated Parties [Domain]
Related Party
Measurement Input Remaining Term [Member]
Measurement input remaining term.
Remaining Term [Member]
Class of Warrant or Right [Line Items]
Legal Entity [Axis]
Increase Decrease In Operating Capital [Abstract]
Increases (decreases) in cash caused by changes in operating assets and liabilities:
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
Balance as of December 31, 2024 (in dollars per share)
Balance as of June 30, 2025 (in dollars per share)
Measurement Input, Fair Value Of Common Stock [Member]
Measurement input, fair value of common stock.
Fair Value of Common Stock [Member]
Fair Value, Recurring and Nonrecurring [Table]
Additional Paid In Capital [Member]
Additional Paid-in Capital [Member]
Regular Purchase Price Per Share Threshold Percentage
Regular purchase price per share threshold percentage.
Regular purchase price per share threshold percentage
Measurement Frequency [Domain]
Share Repurchase Program, Authorized, Amount
Authorized amount of repurchase of stock
Statement of Income Location, Balance [Axis]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in accounting principle, accounting standards update, adoption date
Change in Accounting Principle, Accounting Standards Update, Adoption Date
Trading Symbol
Trading Symbol
Subsequent Event Type [Axis]
Floor Price
Floor price.
Floor price
Net Cash Provided By Used In Financing Activities [Abstract]
Cash flows provided by financing activities:
Fair Value, Recurring [Member]
Recurring Basis [Member]
Accrued payments due to NanoTx
Accrued License Payable
Accrued license payable.
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Equity Components [Axis]
Statement Equity Components [Axis]
Equity Components
Line of credit
Line of Credit, Current
Nonoperating Income Expense
Interest expense
Interest expense
Total other income (expense)
Equity Component [Domain]
Equity Component [Domain]
Equity Component
Schedule Of Share Based Compensation Activity Table [Text Block]
Stock Option Activity
Total investments
Investments
Investments, Total
Biocept Asset Acquisitions [Member]
Biocept asset acquisitions.
Increase Decrease In Other Current Assets
Other current assets
Prepaid insurance
Prepaid Insurance
Gross Proceeds from Issuance of Common Stock
Gross proceeds from issuance of common stock.
Aggregate gross proceeds from sales of common stock
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
Stock option contractual term
March Two Thousand Twenty Five Series A Warrants [Member]
March Two Thousand Twenty Five Series A Warrants Member.
March 2025 Series A Warrants
Department of Defense Award [Member]
Department of defense award.
Maximum [Member]
Maximum [Member]
Statistical Measurement
Statistical Measurement [Axis]
Range [Axis]
Common stock, $0.001 par value; 100,000,000 shares authorized; 36,123,833 and 33,601,373 issued and outstanding at March 31, 2023 and December 31, 2022, respectively
Voting stock, value
Common Stock Value
Common stock, $0.001 par value; 2,000,000,000 shares authorized; 92,438,432 shares issued; and 92,180,007 shares outstanding as of June 30, 2025, and 100,000,00 shares authorized; 6,154,758 shares issued; and 5,896,333 shares outstanding as of December 31, 2024, respectively
Net Income (Loss) Available to Common Stockholders, Diluted
Net loss per share of common stock - diluted
March 2025 Series A and Series B Warrants
March Two Thousand Twenty Five Series A Warrants and Series B Warrants [Member]
March 2025 Series A and March 2025 Series B common stock warrants.
Lincoln Park Purchase Agreement [Member]
Lincoln Park Purchase Agreement.
Lincoln Park Purchase Agreement
Minimum Bid Requirement Date
Minimum bid requirement date.
Minimum bid requirement date
Preferred Stock Shares Authorized
Preferred stock, shares authorized (in shares)
Issuance of common stock, prefunded warrants and warrants, net of offering costs (in shares)
Issuance Of Common Stock Shares, Prefunded Warrants And Warrants, Net Of Offering Costs
Issuance of common stock shares, prefunded warrants and warrants, net of offering costs.
February Two Thousand Twenty Five Warrants [Member]
February two thousand twenty five warrants.
February 2025 Warrants [Member]
Percentage of commission on gross proceeds from sale of common stock.
Percentage of Commission on Gross Proceeds from Sale of Common Stock
Percentage of commission on gross proceeds from sale of common stock
Revenue from Contract with Customer [Text Block]
Grant Revenue
Entity Registrant Name
Entity Registrant Name
Other Deferred Costs, Net
Other Deferred Costs, Net, Total
Deferred costs (Note 7)
Additional Period for Regain Compliance on Achievement of Compliance
Additional period for regain compliance on achievement of compliance.
Additional period for regain compliance on achievement of compliance
Series B Warrant [Member]
Series B Warrant.
Personnel Related Expenses [Member]
Personnel Related Expenses [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]
Purchase of treasury stock (in Shares)
Treasury Stock, Shares, Acquired
Purchase of treasury stock (in Shares)
Financing expenses
Financing Expenses
Financing expenses.
Financing expenses
Additional Paid In Capital
Additional paid-in capital
Additional Paid in Capital, Total
Amendment and Restatements May 2024 Private Placement [Member]
Amendment and restatements May 2024 private placement.
Subsequent Events [Abstract]
Accounts Payable And Accrued Liabilities Current
Accounts payable and accrued expenses
Accounts payable and accrued expenses, Total
Measurement Frequency [Axis]
Total cash payment
Payments to Acquire Productive Assets
Payments to Acquire Productive Assets, Total
Total cash payment
Proceeds from Issuance of Common Stock
Proceeds from sale of common stock under Lincoln Park Purchase Agreement
Cash proceeds from sale of common stock
Subscription and Investment Representation Agreement
Subscription Agreement [Member]
Subscription Agreement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]
Summary of Key Level 3 Inputs Used in Valuation of Warrants Liability at Fair Value
Provides an entity's explanation that the preparation of financial statements in conformity with generally accepted accounting principles requires the use of management estimates.
Use Of Estimates [Text Block]
Use of Estimates
Entity Common Stock Shares Outstanding
Entity Common Stock, Shares Outstanding
Unpaid Offering Costs.
Unpaid Offering Costs
Unpaid offering cost
Liability Class [Axis]
Measurement Input Interest Rate [Member]
Measurement input interest rate.
Interest Rate [Member]
Payments To Acquire Property Plant And Equipment
Purchases of property and equipment
Payments to Acquire Property, Plant, and Equipment, Total
Assets
Total assets
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
Exercisable at June 30, 2025
Income Statement [Abstract]
Securities Purchase Agreement [Member]
Securities purchase agreement.
Securities Purchase Agreement [Member]
Legal Fees
Legal fees
Number of shares issued
Sale of Stock, Number of Shares Issued in Transaction
Series A Warrant.
Series A Warrant [Member]
Sale of common stock, net
Issue and sale of share
Issuance of common stock (in shares)
Earnings Per Share Diluted
Net loss per share, diluted
Net loss per share of common stock - diluted
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Schedule of Segment Expenses
Asset Acquisition [Axis]
City Area Code
City Area Code
Redemption of Notes by Issuance of Common Stock, Prefunded Warrants and Warrants
Redemption of notes by issuance of common stock, prefunded warrants and warrants.
Redemption of notes by issuance of common stock, pre-funded warrants and warrants
Proceeds from credit facility
Proceeds from Lines of Credit
Proceeds from Lines of Credit, Total
Original loan amount
Aggregate principal amount
Debt Instrument Face Amount
Non-Cash Financing Expense
Non-cash financing expense.
Noncash financing expenses
Cashless warrants excercised for common stock
Number of Cashless Warrants Excercised for Common Stock
Number of cashless warrants excercised for common stock.
Segment Reporting Information [Line Items]
Stock split conversion ratio
Stockholders' Equity Note, Stock Split, Conversion Ratio
Lease Expiration Date1
Operating leases, expiration date
Number Of Preferred Stock Shares Exercised.
Number Of Preferred Stock Shares Exercised
Number of preferred stock, shares converted
Property Plant And Equipment Net
Property and equipment, net
Property, Plant and Equipment, Net, Total
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
Cash and cash equivalents at end of period
Cash and cash equivalents at beginning of period
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total
Operating Income Loss
Operating loss
Percentage of credit facility cannot exceed collateralized marketable securities
Percentage of Credit Facility Cannot Exceed Collateralized Marketable Securities
Percentage of credit facility cannot exceed collateralized marketable securities.
Retained Earnings [Member]
Accumulated Deficit [Member]
Cash and Cash Equivalents [Axis]
Share-based compensation expense
Share Based Compensation
Share-Based Payment Arrangement, Noncash Expense, Total
Measurement Input, Price Volatility [Member]
Volatility [Member]
Payments of Stock Issuance Costs
Costs from sale of common stock
Restricted beneficial ownership level result of exercise of warrant to receive pre-funded warrant
Restricted Beneficial Ownership Level Result of Exercise of Warrant To Receive Pre-funded Warrant
Restricted beneficial ownership level result of exercise of warrant to receive pre-funded warrant.
Share Repurchase Program, Authorized, Number of Shares
Number of shares agreed to return
Manufacturing Agreement with SpectronRX [Member]
Manufacturing Agreement with SpectronRX.
Manufacturing Agreement with SpectronRX
Stock Issued During Period, Value, Exercise of Series B Warrants
Stock issued during period, value, exercise of Series B warrants.
Exercise of March 2025 Series B Warrants
Operating Lease Liability Noncurrent
Noncurrent operating lease liability
Fair Value, Inputs, Level 1 [Member]
Level 1 [Member]
Class Of Stock [Line Items]
Class of Stock [Line Items]
Net Cash Provided By Used In Financing Activities
Net cash provided by financing activities
Grant revenue receivable
Grants Receivable
Change in accounting principle, accounting standards update, adopted
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]
Asset Acquisition [Abstract]
Investments, Fair Value Disclosure
Investments, Fair Value Disclosure, Total
Investments
Schedule of Other Current Assets [Table Text Block]
Other Current Assets
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
Summary of Warrants Outstanding
Grant [Member]
Grant [Member]
US Government Corporations and Agencies Securities [Member]
Government Agency Bonds [Member]
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]
Schedule of Antidilutive Securities Excluded from Diluted Loss per Share
Entity Interactive Data Current
Entity Interactive Data Current
Pre-Funded Warrants [Member]
Pre-funded warrants member.
Pre-funded Warrants [Member]
Statement of Income Location, Balance [Domain]
Net Cash Provided By Used In Operating Activities [Abstract]
Cash flows used in operating activities:
Asset Acquisition [Line Items]
Repayments of Lines of Credit
Repayment of line of credit facility
Accretion (Amortization) of Discounts and Premiums, Investments
Accretion of discount on short-term investments
Segment Reporting, Expense Information Used by CODM, Type [Extensible Enumeration]
March Two Thousand Twenty Five Prefunded Warrants [Member]
March Two Thousand Twenty Five Prefunded Warrants Member.
March 2025 Prefunded Warrants [Member]
Exchange [Member]
Exchange.
Recorded Unconditional Purchase Obligation [Line Items]
Recorded Unconditional Purchase Obligation [Line Items]
Entity Tax Identification Number
Entity Tax Identification Number
Series A Warrant and Series B Warrant [Member]
Series a warrant and series b warrant.
Share Price
Closing price per share
Repayments of Notes Payable
Repayment of notes payable
Local Phone Number
Local Phone Number
Cancer prevention and research institute of texas contract.
Cancer Prevention And Research Institute Of Texas Contract [Member]
CPRIT Contract [Member]
May Two Thousand Twenty Four Series A Warrants [Member]
May Two Thousand Twenty Four Series A Warrants Member.
May 2024 Series A Warrants [Member]
2020 Plan [Member]
Stock based compensation 2020 equity incentive plan.
Stock Based Compensation2020 Equity Incentive Plan [Member]
Consecutive business days
Debt Instrument, Convertible, Threshold Trading Days
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax
Grant revenue recognized
Grant revenue
Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]
Class Of Stock [Domain]
Class of Stock
Sale closed date
Sale of Stock, Transaction Date
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
Securities remaining and available for future issuances (in shares)
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
Weighted average period for recognition of cost
Proceeds From Sale of Common Stock, Prefunded Warrants and Warrants
Proceeds from sale of common stock, prefunded warrants and warrants.
Proceeds from sale of common stock, pre-funded warrants and warrants
Schedule Of Stock By Class [Table]
Schedule Of Stock By Class [Table]
Debt Instrument Floor Rate
Debt instrument floor rate.
Debt instrument floor rate
Entity Emerging Growth Company
Entity Emerging Growth Company
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
Vested and expected to vest at June 30, 2025